GLP-1/GIP Dual Target Weight Loss Innovative Drug

This product is the world's first approved dual target cell therapy product based on mRNA LNP. By expressing CAR that can specifically recognize leukocyte differentiation antigen 19 (CD19) and B-cell maturation antigen (BCMA), it accurately identifies and eliminates CD19 and BCMA positive cells in patients' bodies, thereby achieving therapeutic goals. The synergistic effect of dual targets can eliminate pathogenic cells from the source, fundamentally improve the patient's condition, and solve the pain points that traditional treatments cannot cure and are prone to recurrence. Preclinical studies have shown that this product can significantly kill CD19 and BCMA positive cells, and has good safety and efficacy.

The clinical indication approved this time is relapsed and refractory systemic lupus erythematosus. In addition, this product is expected to be used for the treatment of other B cell/plasma cell-mediated autoimmune diseases such as myasthenia gravis (MG), rheumatoid arthritis (RA), and anti neutrophil cytoplasmic antibody (ANCA) - related vasculitis. It can also be extended to relapsed/refractory multiple myeloma (MM), B-cell lymphoma, and other hematological tumors, and has high clinical development value. The approval of the clinical trial of this product is another important achievement of our group's layout in the field of cell therapy, laying a good foundation for the development of cell therapy products including in vivo generated CAR-T.

Zilebesiran is a subcutaneous RNAi therapy developed by Alnylam based on its enhanced stable chemical PLUS (ESC+) GaINAc conjugate technology. It reduces angiotensin levels by targeting the synthesis of angiotensinogen (AGT), the most upstream component of the renin angiotensin aldosterone system (RAAS), a classic pathway for blood pressure regulation. Ultimately, it leads to a sustained decrease in blood pressure. In July 2023, Roche and AInylam reached an agreement to obtain the cooperative development and commercialization rights of the drug for a total transaction value of up to $2.8 billion. In September 2025, the two parties launched Zilebesiran's first phase IV clinical trial. ZENISH).

This study is a global, randomized, double-blind, placebo-controlled clinical trial (n=11000) aimed at evaluating the effectiveness and safety of Zilebesiran (300mg, subcutaneous injection, once every 6 months) combined with standard treatment (OC) compared to placebo combined with SOC in reducing the incidence of major cardiovascular adverse events (MACE) in hypertensive adult patients with diagnosed cardiovascular disease or poor blood pressure control at high risk of cardiovascular disease. The primary endpoint of the study is the time to the first occurrence of cardiovascular death, non fatal myocardial infarction (MI), non fatal stroke, or heart failure (HF) within 5 years of treatment.

On June 3, 2026, Ascidian Therapeutics announced today that it has reached a global research collaboration and licensing agreement with Ei Lily and Company. Both parties will jointly discover and develop therapies for undisclosed monogenic kidney diseases, and Ei Lily has the right to choose to expand the collaboration to other targets.
Ascidian's RNA exon editor can edit multiple complete exons at the kilobase scale to repair genetic instructions that cause diseases. This technology is designed specifically to address large genes or genes with high mutation diversity, expanding the boundaries of gene drugs.

According to the terms of the agreement, Eli Lilly will obtain exclusive, target specific rights to Ascidian's RNA exon editing technology for undisclosed kidney disease targets. Ascidian will lead drug discovery and selected preclinical activities, while Eli Lilly will be responsible for additional preclinical research, clinical development, production, and commercialization. Ascidian is eligible for up to $1.9 billion in payments, including prepayments, development and commercialization milestone payments, and tiered royalties based on global sales. Ascidian reserves the right to independently or jointly develop other targets in the field of kidney with other partners.

The total value of the partnership project is up to $2 billion, including a $30 million advance payment (including cash and Inceptive equity subscription). In addition, Inceptive is eligible for additional interim payments based on the achievement of milestones such as preclinical research, regulatory approvals, and commercial sales. This collaboration combines AInvlam's leadership position in the RNAi field with lnceptive's foundational models and AI expertise, aiming to catalyze and accelerate the development of nucleic acid drug design. Innovative focuses on developing models for stem based drugs, such as RNAi therapy pioneered by Alnylam.

Alnylam's platform: a research and development engine that has produced six marketed drugs and has over 20 years of proprietary siRNA data support. Inceptive Life Foundation Model: Suitable for A! Models based on sequential drugs, it can generalize and continuously self optimize across different projects. The aim of this collaboration is to model the target mRNA and jointly explore sequence space and novel chemical modifications to enhance efficacy and therapeutic effects, while predicting the optimal therapeutic candidate molecules in preclinical models for further development by AInyiam, thereby promoting advances in SiRNA design. Its goal is to help Alnylam prioritize the screening of the most promising molecules and improve experimental efficiency.